Pharmaceutical Ethics Comes to Life in Therapeutic Innovation & Regulatory Science Wendy Lipworth Ethics Special Section: Guest Editorial 30 December 2015 Pages: 324 - 325
Medicines in Pregnancy Forum: Proceedings on Ethical and Legal Considerations David B. ClemowMartha R. NolanLode Dewulf Ethics Special Section: Meeting Report 30 December 2015 Pages: 326 - 332
Confounding Issues in Cancer Progress—The Impact of Investor Requirements on Senior Management Compensation and Regulatory Decisions: Tivozanib and Aveo Pharmaceuticals Josephine C. BabiarzFrancis MelaragniPranati Kuchimanchi Ethics Special Section: Analytical Report 30 December 2015 Pages: 333 - 341
Ethical Considerations for Increased Transparency and Reproducibility in the Retrospective Analysis of Health Care Data Matthew D. Rotelli Ethics Special Section: Analytical Report 30 December 2015 Pages: 342 - 347
The Ethics Around Drug Labels and Generic Medicines Richard DayWendy LipworthNarcyz Ghinea Ethics Special Section: Commentary 30 December 2015 Pages: 348 - 351
Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors Mitchell KlopfensteinLuann E. Van CampenTimothy Garnett Ethics Special Section: Analytical Report Open access 30 December 2015 Pages: 352 - 358
x? Narcyz GhineaWendy LipworthIan Kerridge Ethics Special Section: Analytical Report 30 December 2015 Pages: 359 - 363
Improving the Legitimacy of Medicines Funding Decisions: A Critical Literature Review Jessica PaceSallie-Anne PearsonWendy Lipworth Ethics Special Section: Review 30 December 2015 Pages: 364 - 368
Focus on Health Literacy: Recommendations to Improve European Union Risk Management Plan Public Summaries Anne WolkaKatherine SimpsonLinda Neuhauser Policy: Original Research 30 December 2015 Pages: 369 - 376
Medication Guide Reading Behaviors and Attitudes Among Subjects With Migraine, Asthma, or COPD Kristen B. BibeauRachael L. DiSantostefanoDavid Hinds Policy: Original Research 30 December 2015 Pages: 377 - 386
Analysis of Social Media Interactions Between Pharmaceutical Companies and Consumers: The Power of the “Like” William JacksonBoas ParkEvelyn Hermes-DeSantis Policy: Original Research 30 December 2015 Pages: 387 - 391
Lessons Learned From Hundreds of Thorough QT Studies Joanne ZhangHuifang ChenNorman Stockbridge Product Safety: Original Research 30 December 2015 Pages: 392 - 397
Choosing Appropriate Metrics to Evaluate Adverse Events in Safety Evaluation Ying ZhouChunlei KeSteven Snapinn Product Safety: Review 30 December 2015 Pages: 398 - 404
Early Clinical Development Planning via Biomarkers, Clinical Endpoints, and Simulation: A Case Study to Optimize for Phase 3 Dose Selection Bret MusserJames BologneseNitin Patel Clinical Trials: Original Research 30 December 2015 Pages: 405 - 414
The Life Sciences Translational Challenge: The European Perspective Richard W. BarkerJack W. Scannell Product Development and Innovation: Review 30 December 2015 Pages: 415 - 424
Benefit-Risk Evaluation and Decision Making: Some Practical Insights Michael W. ColopyC. V. DamarajuZhong Yuan Product Development and Innovation: Meeting Report 30 December 2015 Pages: 425 - 433
Pre—Investigational New Drug Meetings With the FDA: Evaluation of Meeting Content and Characteristics of Applications for New Drug and Biologic Products Hong H. VuAnne R. Pariser Regulatory Science: Original Research 30 December 2015 Pages: 434 - 442
Treatment Outcomes of Nevirapine- Versus Efavirenz-Based Highly Active Antiretroviral Therapy Regimens Among Antiretroviral-Naive Adult Patients in Ethiopia: A Cohort Study Muktar Sano KedirDesta Hiko GemedaSultan Suleman Global Perspectives: Original Research 30 December 2015 Pages: 443 - 449